What are Regeneron's main drugs?
Regeneron Pharmaceuticals develops and commercializes an innovative portfolio of advanced biologic medications targeting immunology, oncology, ophthalmology, and rare diseases. Its flagship commercial products include Dupixent, a blockbuster therapy for atopic dermatitis, asthma, and chronic rhinosinusitis; Eylea and Eylea HD, leading treatments for retinal eye conditions such as macular degeneration; Libtayo, an advanced immunotherapy for various cancers; and Praluent, a specialized treatment for managing cholesterol levels. These breakthrough treatments anchor the company's global leadership in biotechnology.
Related FAQs
BlackRock does not own Rentokil Initial PLC, but it is a major institutional investor in the company. As of March 2026, BlackRock increased its total holding in Rentokil to 12.
Market consensus recommendations for Regeneron Pharmaceuticals (NASDAQ: REGN) generally reflect favorable buy or moderate accumulation ratings among biotechnology equity research analysts.
Regeneron Pharmaceuticals continues to advance its therapeutic pipeline with recent regulatory approvals and label expansions, notably including extended dosing interval approvals for Eylea HD up to every 20 weeks for retinal conditions.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals' best-selling and most financially lucrative product is Dupixent, an innovative monoclonal antibody co-developed and commercialized in strategic partnership with Sanofi.
Eli Lilly and Company is the most valuable and wealthiest pharmaceutical enterprise in the world, commanding a staggering market capitalization exceeding $1.1 trillion USD.
Regeneron Pharmaceuticals, Inc.
Gold Resource Corporation is typically evaluated by precious metals and small-cap mining investors with a cautious outlook rather than a consensus strong buy rating.
Market consensus recommendations for Regeneron Pharmaceuticals (NASDAQ: REGN) frequently highlight its strong scientific pipeline, leadership in antibody technology, and consistent revenue generation from major specialty medicines as compelling long-...
Evaluating whether to sell your Regeneron Pharmaceuticals, Inc. (REGN) stock involves analyzing the biotechnology giant's robust product pipeline, patent protection status, and ongoing clinical trial developments.
Renesas Electronics Corporation demonstrates solid financial performance, operating as a global semiconductor powerhouse specializing in microcontrollers, analog devices, power management, and system-on-chip solutions for automotive, industrial, and ...
Yes, you can buy stock in Revolution Medicines Inc. It is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "RVMD.
Regeneron's monoclonal antibody cocktail (casirivimab and imdevimab) is no longer widely utilized or authorized for treating COVID-19 because circulating SARS-CoV-2 variants have developed substantial resistance to its neutralizing mechanisms.